ENERGYNEST
30.3.2017 14:32:09 CEST | Business Wire | Press release
Tata Steel operates one of Europe’s largest steel production facilities in IJmuiden / Netherlands. Currently, large energy potentials are released to the atmosphere, through intermittent high temperature exhaust gases. Implicit economic benefits of this waste heat remain untapped. Finding an effective way to recover and reuse this energy will not only yield attractive economic returns, but also significant CO2 emission reductions.
In order to fully utilize such effects, Tata Steel is now commencing the implementation of an EnergyNest Thermal Energy Storage (TES) demo project as a ‘lighthouse initiative’. The IJmuiden demo will utilize exhaust gas energy from steel production to cover own energy demands in the facility – resulting in reduced natural gas consumption and CO2 emissions.
“The steel industry has already undertaken huge efforts to reduce emissions, and to go any further simply requires new technologies. This demo installation is just a first step for Tata’s IJmuiden plant. We are proud to be yet again the global leader for implementing environmentally friendly solutions with a strong business case.” says Gerard Jägers, Program Manager Energy Efficiency. A joint assessment of effects for a full-scale implementation of the EnergyNest throughout the IJmuiden facility shows impressive results: a 500 MWh TES can yield annual savings of 2.3 million GJ of natural gas (65 million Nm3 ) and 130.000 tons of emitted CO2 . EnergyNest CEO Dr. Christian Thiel: “These savings compensate for annual CO2 emissions of 90.000 cars. And at the same time a full-scale implementation offers extremely attractive economics, which supplement such a project with a very healthy business rationale. We are very proud to support Tata Steel in its game-changing approach towards carbon footprint reduction.”
The EnergyNest TES technology is based on globally available materials that are fully recyclable. Due to its very low cost-base, a full-scale implementation in the IJmuiden facility – together with Jord as acting EPC – has a payback of less than three years, based on today’s natural gas prices. Should natural gas prices increase the payback period is reduced to less than two years. Adopting this innovative technology, Tata Steel IJmuiden will strengthen the facility's status as a global technology frontrunner.
About EnergyNest: EnergyNest (EN) is a technology company based in Billingstad, close to the Norwegian capital Oslo. Founded in 2011, EN has developed a unique and patented design for a modular solid-state thermal energy storage (“TES”) systems and a tailored solid state storage medium (HEATCRETE®) that enables a very simple, efficient, and low cost energy storage system (“EN technology”). The EN technology can be applied in various market segments, that require high temperature thermal energy storage for many hours or days. EN’s technology is field proven at the Masdar Institute, UAE.
About Tata Steel: Tata Steel is one of the world leading manufacturers of raw steel, rolled and coated products. It is also one of the world’s most geographically diversified steel producers, serving many demanding markets worldwide, including Aerospace, Automotive, Construction, Consumer Products, Defence & Security, Energy & Power, Lifting & Excavating and Packaging. Tata Steel is committed to the design of more sustainable products that contribute to solutions, which are lighter, last longer and use fewer resources to produce.
About Jord: Jord Oil & Gas Systems B.V. is a Rotterdam based company that designs, manufactures, commissions, and services custom-engineered process equipment, modular skids, and turnkey plants for the steel, oil and gas, chemical and petrochemical industries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005611/en/
Contact:
EnergyNest
Thomas Palkovich
Commercial Director
Mob:
+47 982 08 384
Email: tp@energy-nest.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
